Tuesday, May 19, 2020 Daily Archives

Innovative Closed Process CAR-T Cell Therapy Platform to Streamline Approach for Manufacturing with Great Predictability

by

This webcast features: Tatiana Golovina, Senior Director, Cell Therapy Process Development, WuXi Advanced Technologies For many years, the primary forms of cancer treatment have been chemotherapy, radiation, and surgery. An amazing breakthrough known as chimeric antigen receptor (CAR) T-cell therapy is being studied in the treatment of various types of cancer, including acute and chronic lymphoblastic leukemia, non-Hodgkin lymphoma, myeloma, and solid tumors. Developing innovative advanced therapies is one of our greatest opportunities to dramatically improve patients’ lives. WuXi Advanced…

May 19, 2020

MilliporeSigma reports robust Q1 on back of COVID-19

by

Merck’s MilliporeSigma is the latest to report bioprocess resilience in the face of COVID-19, and like others has even seen an increase in sales and projects. MilliporeSigma, the life sciences division of Germany’s Merck, saw sales of €1.8 billion ($2 billion) in the first quarter of 2020, up 6.5% on the same period last year, fueled in part by its Process Solutions business unit, which saw sales grow organically by 13.2% (another example of double-digit growth in the biopharma equipment…

May 19, 2020

J&J brings German CDMO Vibalogics on board for COVID vaccine project

by

Vibalogics will provide clinical trial material for J&J’s COVID-19 vaccine candidate from its site in Cuxhaven, Germany. J&J is also working with Catalent and Emergent. Johnson & Johnson (J&J) began working on a vaccine against COVID-19 in early January once the coronavirus sequence became first available, and at the end of March identified the lead its lead candidate along with two backups. Since then, the firm has worked on ensuring production of clinical and – potentially – commercial supply, with a pledge…

May 19, 2020

Inhouse manufacturing helping speedy progression of mRNA COVID vaccine, says Moderna

by

Moderna Therapeutics believes its Norwood, Massachusetts manufacturing plant is a “competitive strategic advantage†in the race to develop and scale-up a vaccine against COVID-19. Moderna released data from a small Phase I study of its candidate mRNA-1273 yesterday. The trial, conducted by the National Institute of Allergy and Infectious Diseases, showed signs that the candidate elicits antibodies at levels comparable to those found in the blood of dozens of patients who have recovered from COVID-19, caused by the novel coronavirus (SARS-CoV-2).…

May 19, 2020